Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism

yayoi matsuda, Hisaya Kawate, Chitose Matsuzaki, Ryuichi Sakamoto, Kimitaka Shibue, Ohnaka Keizo, Keizo Anzai, Masatoshi Nomura, Ryoichi Takayanagi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Primary aldosteronism (PA) is associated with a higher rate of cardiovascular events than essential hypertension. Although adrenalectomy has been reported to reduce carotid intima-media thickness (IMT) in patients with PA, the effects of the selective aldosterone blocker, eplerenone, on vascular damage in these patients remains unclear. To evaluate the effects of eplerenone on vascular status in PA patients, we sequentially measured carotid IMT (using computer software to calculate an average IMT for accurate and reproducible evaluation) in 22 patients including 8 patients treated by unilateral adrenalectomy and 14 patients treated with eplerenone for 12 months. Patients who underwent adrenalectomy showed significant reductions in aldosterone concentration (from 345 ± 176 pg/mL to 67 ± 34 pg/mL; P<0.01) and IMT (from 0.67 ± 0.07 mm to 0.63 ± 0.09 mm; P<0.05) 6 months after surgery. Patients treated with eplerenone showed significant reductions in IMT from baseline (0.75 ± 0.10 mm) to 6 (0.71 ± 0.11 mm; P<0.05) and 12 (0.65 ± 0.09 mm; P<0.01) months, although plasma aldosterone level increased significantly, from 141 ± 105 pg/mL to 207 ± 98 pg/mL (P<0.05). Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status. Carotid IMT may be a useful marker for evaluating the effectiveness of eplerenone in patients with PA.

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalEndocrine Journal
Volume63
Issue number3
DOIs
Publication statusPublished - Mar 31 2016

Fingerprint

Carotid Intima-Media Thickness
Hyperaldosteronism
Adrenalectomy
Aldosterone
Blood Vessels
eplerenone
Potassium
Software
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. / matsuda, yayoi; Kawate, Hisaya; Matsuzaki, Chitose; Sakamoto, Ryuichi; Shibue, Kimitaka; Keizo, Ohnaka; Anzai, Keizo; Nomura, Masatoshi; Takayanagi, Ryoichi.

In: Endocrine Journal, Vol. 63, No. 3, 31.03.2016, p. 249-255.

Research output: Contribution to journalArticle

matsuda, yayoi ; Kawate, Hisaya ; Matsuzaki, Chitose ; Sakamoto, Ryuichi ; Shibue, Kimitaka ; Keizo, Ohnaka ; Anzai, Keizo ; Nomura, Masatoshi ; Takayanagi, Ryoichi. / Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. In: Endocrine Journal. 2016 ; Vol. 63, No. 3. pp. 249-255.
@article{3e8bb3230ec14c4782aad873456d80fb,
title = "Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism",
abstract = "Primary aldosteronism (PA) is associated with a higher rate of cardiovascular events than essential hypertension. Although adrenalectomy has been reported to reduce carotid intima-media thickness (IMT) in patients with PA, the effects of the selective aldosterone blocker, eplerenone, on vascular damage in these patients remains unclear. To evaluate the effects of eplerenone on vascular status in PA patients, we sequentially measured carotid IMT (using computer software to calculate an average IMT for accurate and reproducible evaluation) in 22 patients including 8 patients treated by unilateral adrenalectomy and 14 patients treated with eplerenone for 12 months. Patients who underwent adrenalectomy showed significant reductions in aldosterone concentration (from 345 ± 176 pg/mL to 67 ± 34 pg/mL; P<0.01) and IMT (from 0.67 ± 0.07 mm to 0.63 ± 0.09 mm; P<0.05) 6 months after surgery. Patients treated with eplerenone showed significant reductions in IMT from baseline (0.75 ± 0.10 mm) to 6 (0.71 ± 0.11 mm; P<0.05) and 12 (0.65 ± 0.09 mm; P<0.01) months, although plasma aldosterone level increased significantly, from 141 ± 105 pg/mL to 207 ± 98 pg/mL (P<0.05). Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status. Carotid IMT may be a useful marker for evaluating the effectiveness of eplerenone in patients with PA.",
author = "yayoi matsuda and Hisaya Kawate and Chitose Matsuzaki and Ryuichi Sakamoto and Kimitaka Shibue and Ohnaka Keizo and Keizo Anzai and Masatoshi Nomura and Ryoichi Takayanagi",
year = "2016",
month = "3",
day = "31",
doi = "10.1507/endocrj.EJ15-0362",
language = "English",
volume = "63",
pages = "249--255",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism

AU - matsuda, yayoi

AU - Kawate, Hisaya

AU - Matsuzaki, Chitose

AU - Sakamoto, Ryuichi

AU - Shibue, Kimitaka

AU - Keizo, Ohnaka

AU - Anzai, Keizo

AU - Nomura, Masatoshi

AU - Takayanagi, Ryoichi

PY - 2016/3/31

Y1 - 2016/3/31

N2 - Primary aldosteronism (PA) is associated with a higher rate of cardiovascular events than essential hypertension. Although adrenalectomy has been reported to reduce carotid intima-media thickness (IMT) in patients with PA, the effects of the selective aldosterone blocker, eplerenone, on vascular damage in these patients remains unclear. To evaluate the effects of eplerenone on vascular status in PA patients, we sequentially measured carotid IMT (using computer software to calculate an average IMT for accurate and reproducible evaluation) in 22 patients including 8 patients treated by unilateral adrenalectomy and 14 patients treated with eplerenone for 12 months. Patients who underwent adrenalectomy showed significant reductions in aldosterone concentration (from 345 ± 176 pg/mL to 67 ± 34 pg/mL; P<0.01) and IMT (from 0.67 ± 0.07 mm to 0.63 ± 0.09 mm; P<0.05) 6 months after surgery. Patients treated with eplerenone showed significant reductions in IMT from baseline (0.75 ± 0.10 mm) to 6 (0.71 ± 0.11 mm; P<0.05) and 12 (0.65 ± 0.09 mm; P<0.01) months, although plasma aldosterone level increased significantly, from 141 ± 105 pg/mL to 207 ± 98 pg/mL (P<0.05). Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status. Carotid IMT may be a useful marker for evaluating the effectiveness of eplerenone in patients with PA.

AB - Primary aldosteronism (PA) is associated with a higher rate of cardiovascular events than essential hypertension. Although adrenalectomy has been reported to reduce carotid intima-media thickness (IMT) in patients with PA, the effects of the selective aldosterone blocker, eplerenone, on vascular damage in these patients remains unclear. To evaluate the effects of eplerenone on vascular status in PA patients, we sequentially measured carotid IMT (using computer software to calculate an average IMT for accurate and reproducible evaluation) in 22 patients including 8 patients treated by unilateral adrenalectomy and 14 patients treated with eplerenone for 12 months. Patients who underwent adrenalectomy showed significant reductions in aldosterone concentration (from 345 ± 176 pg/mL to 67 ± 34 pg/mL; P<0.01) and IMT (from 0.67 ± 0.07 mm to 0.63 ± 0.09 mm; P<0.05) 6 months after surgery. Patients treated with eplerenone showed significant reductions in IMT from baseline (0.75 ± 0.10 mm) to 6 (0.71 ± 0.11 mm; P<0.05) and 12 (0.65 ± 0.09 mm; P<0.01) months, although plasma aldosterone level increased significantly, from 141 ± 105 pg/mL to 207 ± 98 pg/mL (P<0.05). Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status. Carotid IMT may be a useful marker for evaluating the effectiveness of eplerenone in patients with PA.

UR - http://www.scopus.com/inward/record.url?scp=84961989610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961989610&partnerID=8YFLogxK

U2 - 10.1507/endocrj.EJ15-0362

DO - 10.1507/endocrj.EJ15-0362

M3 - Article

VL - 63

SP - 249

EP - 255

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 3

ER -